title: [Clinical and biological effectiveness of antiretroviral therapy in the ANRS 1215 cohort].
abstract: In 1998, the cohort ANRS 1215 was launched in Senegal with one of the first African antiretroviral treatment programs. Four hundred forty four HIV-infected adults started on ART were included between 1998 and 2004, and followed up to 2010. Mortality before 6 months was 15.6/100 person-year (PY) and associated to the initial disease severity. It decreased to 3.36/100 PY thereafter. The cumulative risks of virologic failure at 60 months and of drug resistance at 48 months were 25% and 16%, respectively.
authors.affiliation: UMI 233 TransVIHMI, IRD (Institut de recherche pour le développement), TRANSVIHMI, UMI 233, Dakar, Sénégal, pierre.debeaudrap@ird.fr.
authors.forename: P
authors.initials: P
authors.lastname: De Beaudrap
authors.forename: A
authors.initials: A
authors.lastname: Diouf
authors.forename: K
authors.initials: K
authors.lastname: Bousso Niang
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008297:Male; D011379:Prognosis; D012675:Senegal / Q000453:epidemiology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents